Medinet Co

Medinet Co Net Debt

The Net Debt of Medinet Co (2370.T) as of Oct 27, 2026 is -4.65 B JPY. In the previous year, Net Debt was -4.39 B JPY — a change of 5.83% (lower).

Net Debt

-4.65 BJPY

YoY

5.83%

Last updated:

Net Debt of Medinet Co is 2024 -4.65 B JPY. Net Debt of Medinet Co was 2023 -4.39 B JPY. It decreases by 5.83% lower compared to the previous year.

The Medinet Co Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
-3.31 B JPY
Jan 1, 2018
-2.13 B JPY
Jan 1, 2019
-1.37 B JPY
Jan 1, 2020
-3.63 B JPY
Jan 1, 2021
-4.09 B JPY
Jan 1, 2022
-4.49 B JPY
Jan 1, 2023
-4.39 B JPY
Jan 1, 2024
-4.65 B JPY
The Medinet Co Net Debt history
YEARNet DebtYoY
-4.65 BJPY+5.83%
-4.39 BJPY-2.24%
-4.49 BJPY+9.95%
-4.09 BJPY+12.70%
-3.63 BJPY+164.63%
-1.37 BJPY-35.60%
-2.13 BJPY-35.68%
-3.31 BJPY+29.44%
-2.56 BJPY-9.03%
-2.81 BJPY-44.16%
-5.03 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medinet Co Stock analysis

What does Medinet Co do? MEDINET Co., Ltd. generates revenue through its Cell Processing Industry segment, which offers comprehensive support services for immune cell therapy, including clinical use from companies, universities, and research institutes, outsourcing cell processing for clinical trials, and operating cell culture processing facilities. The Cellular Medical Products segment focuses on research and development to obtain approval for manufacturing and marketing cellular medical products. The company serves clients in the healthcare sector, particularly entities involved in immune cell therapy and cellular medical product development. The Cell Processing Industry segment provides outsourcing services for cell processing in clinical trials, catering to companies, universities, and research institutes seeking specialized processing capabilities. The Cellular Medical Products segment develops cellular medical products requiring regulatory approval, targeting manufacturers and marketers in the medical field. Both segments operate under MEDINET's expertise in cell processing and medical product development. MEDINET's business model relies on delivering specialized cell processing services and supporting the regulatory approval process for cellular medical products. The company's clients include organizations engaged in immune cell therapy research and development, as well as those seeking to commercialize cellular medical products. The dual-segment approach ensures comprehensive coverage of the cell processing and medical product development lifecycle. Medinet Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medinet Co stock

Net Debt of Medinet Co is -4.65 B JPY in 2024.

Net Debt of Medinet Co changed from -4.39 B JPY to -4.65 B JPY, representing a 5.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Medinet Co since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Medinet Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Medinet Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Medinet Co